{"id":"W3004601288","doi":"10.1053/j.gastro.2020.01.047","title":"Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease","year":2020,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":317,"is_retracted":false,"has_abstract":true,"ca_institutions":"St Joseph's Health Care; Robarts Clinical Trials; Western University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Genentech; National Institutes of Health; Dr. Falk Pharma; Tillotts Pharma; Vifor Pharma; Shire; Roche España; AstraZeneca España; Janssen Research and Development; UCB; Bristol-Myers Squibb; Nestlé Health Science; Johnson and Johnson; Teva Pharmaceutical Industries; Meso Scale Diagnostics; Takeda Pharmaceutical Company; Atlantic Healthcare; ActoGeniX; Amgen; Boehringer Ingelheim; Schering-Plough; AbbVie; Ipsen Biopharmaceuticals; Elan; Celgene; Pfizer; Biogen; Merck; Allergan; Seres Therapeutics; AstraZeneca; Boehringer Ingelheim España; Eli Lilly and Company; Janssen Pharmaceuticals; Johns Hopkins University; Crohn's and Colitis Foundation of America; Gilead Sciences; Arrien Pharmaceuticals; California Community Foundation","keywords":"Medicine; Crohn's disease; Randomized controlled trial; Crohn disease; Internal medicine; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005323808,0.001454235,0.003104312,0.0004070982,0.0005023609,0.001096958,0.0007098077,0.001793735,0.004574055],"category_scores_gemma":[0.005202989,0.0008033235,0.002066843,0.0004283238,0.00127373,0.0009916835,0.0005617801,0.002479287,0.000457462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006642779,"about_ca_system_score_gemma":0.001164189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003932842,"about_ca_topic_score_gemma":0.0009724355,"domain_scores_codex":[0.995891,0.003093332,0.0002116234,0.0003498123,0.000176776,0.0002773741],"domain_scores_gemma":[0.9971198,0.0009733449,0.0009195016,0.0002142268,0.0001828371,0.0005903303],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9900022,0.001758693,0.0005950768,0.0002815505,0.0007205238,0.00002323463,0.00002175519,0.00016303,0.0006573796,0.00005478171,0.0002737106,0.005448141],"study_design_scores_gemma":[0.9720137,0.02560365,0.001033595,0.00001984177,0.0004512584,0.00002256205,0.000009210156,0.0002905169,0.0001523968,0.00008532462,0.00031102,0.000006966839],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814527,0.009119655,0.0007635892,0.001338301,0.0009080403,0.003614331,0.0005993854,0.00007656408,0.00212743],"genre_scores_gemma":[0.9913441,0.00201324,0.000887454,0.0008014695,0.0005255389,0.00294428,0.0004877332,0.00001126117,0.0009849109],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005323808,"threshold_uncertainty_score":0.02815533,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.004686295959604195,"score_gpt":0.2075357803414565,"score_spread":0.2028494843818523,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}